Journal of Clinical Oncology, Vol 12, 851-873, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Cancer chemoprevention

SM Lippman, SE Benner and WK Hong
Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.

PURPOSE: To review the most important recent advances in clinical trials and biologic studies within the growing field of chemoprevention. METHODS: The most critical methods issue concerns the definitive end point of phase III trials, which is now cancer incidence. This end point usually needs thousands of subjects monitored for 5 to 10 or more years to determine efficacy. Biologic markers of potential intermediate end points are under intensive study and may one day replace cancer incidence. Validated intermediate end point biomarkers could greatly reduce phase III trial populations, durations, and costs. RESULTS: Randomized clinical trials over the last 5 years have produced significant activity in reversing oral, skin, colon, and cervical premalignancy; in preventing primary skin and stomach cancer; and in preventing second primary tumors associated with head and neck and lung cancer. These clinical advances have been paralleled at the basic science level by elegant molecular studies of premalignant carcinogenesis and of chemopreventive agents' mechanisms of action. One major laboratory advance is the discovery of nuclear retinoic acid receptors and strong evidence of their roles both in carcinogenic progression and in its response to retinoids. CONCLUSION: Chemoprevention has matured greatly in recent years with the significant reversal or suppression of premalignancy by chemopreventive agents in several sites. The future of chemoprevention will be determined largely by several ongoing phase III trials, including trials of retinoids, beta-carotene, and alpha-tocopherol in the aerodigestive tract, of tamoxifen and fenretinide in the breast, and of finasteride in the prostate.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. G. Grabowski and J. L. Moe Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer Chemoprevention Cancer Prevention Research, July 1, 2008; 1(2): 84 - 90. [Abstract] [Full Text] [PDF]

				L.-E Wang, P. Xiong, H. Zhao, M. R. Spitz, E. M. Sturgis, and Q. Wei Chromosome Instability and Risk of Squamous Cell Carcinomas of Head and Neck Cancer Res., June 1, 2008; 68(11): 4479 - 4485. [Abstract] [Full Text] [PDF]

				A. L. Sabichi, S. P. Lerner, E. N. Atkinson, H. B. Grossman, N. P. Caraway, C. P. Dinney, D. F. Penson, S. Matin, A. Kamat, L. L. Pisters, et al. Phase III Prevention Trial of Fenretinide in Patients with Resected Non Muscle-Invasive Bladder Cancer Clin. Cancer Res., January 1, 2008; 14(1): 224 - 229. [Abstract] [Full Text] [PDF]

				S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]

				H. Xu, S. Cheepala, E. McCauley, K. Coombes, L. Xiao, S. M. Fischer, and J. L. Clifford Chemoprevention of Skin Carcinogenesis by Phenylretinamides: Retinoid Receptor-Independent Tumor Suppression Clin. Cancer Res., February 1, 2006; 12(3): 969 - 979. [Abstract] [Full Text] [PDF]

				F. R. Hirsch and S. M. Lippman Advances in the Biology of Lung Cancer Chemoprevention J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197. [Abstract] [Full Text] [PDF]

				I. Bairati, F. Meyer, M. Gelinas, A. Fortin, A. Nabid, F. Brochet, J.-P. Mercier, B. Tetu, F. Harel, B. Masse, et al. A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients J Natl Cancer Inst, April 6, 2005; 97(7): 481 - 488. [Abstract] [Full Text] [PDF]

				J. Sudbo Novel Management of Oral Cancer: A Paradigm of Predictive Oncology Clin. Med. Res., November 1, 2004; 2(4): 233 - 242. [Abstract] [Full Text] [PDF]

				A. L. Sabichi, H. Xu, S. Fischer, C. Zou, X. Yang, V. E. Steele, G. J. Kelloff, R. Lotan, and J. L. Clifford Retinoid Receptor-Dependent and Independent Biological Activities of Novel Fenretinide Analogues and Metabolites Clin. Cancer Res., October 1, 2003; 9(12): 4606 - 4613. [Abstract] [Full Text] [PDF]

				A. L. Sabichi, M.-F. Demierre, E. T. Hawk, C. E. Lerman, and S. M. Lippman Frontiers in Cancer Prevention Research Cancer Res., September 15, 2003; 63(18): 5649 - 5655. [Full Text] [PDF]

				V. A. Papadimitrakopoulou, D. D. Liu, L. Mao, D. M. Shin, A. El-Naggar, H. Ibarguen, J. J. Lee, W. K. Hong, and W. N. Hittelman Biologic Correlates of a Biochemoprevention Trial in Advanced Upper Aerodigestive Tract Premalignant Lesions Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1605 - 1610. [Abstract] [Full Text] [PDF]

				G E Goodman Lung cancer * 1: Prevention of lung cancer Thorax, November 1, 2002; 57(11): 994 - 999. [Abstract] [Full Text] [PDF]

				S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]

				I. Arany, W. E. Whitehead, K. J. Grattendick, I. A. Ember, and S. K. Tyring Suppression of Growth by All-trans Retinoic Acid Requires Prolonged Induction of Interferon Regulatory Factor 1 in Cervical Squamous Carcinoma (SiHa) Cells Clin. Vaccine Immunol., September 1, 2002; 9(5): 1102 - 1106. [Abstract] [Full Text] [PDF]

				X. Wu, S. M. Lippman, J. J. Lee, Y. Zhu, Q. V. Wei, M. Thomas, W. K. Hong, and M. R. Spitz Chromosome Instability in Lymphocytes: A Potential Indicator of Predisposition to Oral Premalignant Lesions Cancer Res., May 1, 2002; 62(10): 2813 - 2818. [Abstract] [Full Text] [PDF]

				S. M. Lippman and W. Ki Hong Cancer Prevention by Delay : Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002. Clin. Cancer Res., February 1, 2002; 8(2): 305 - 313. [Full Text] [PDF]

				J. A. O'Shaughnessy, G. J. Kelloff, G. B. Gordon, A. J. Dannenberg, W. K. Hong, C. J. Fabian, C. C. Sigman, M. M. Bertagnolli, S. P. Stratton, S. Lam, et al. Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development : Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia Clin. Cancer Res., February 1, 2002; 8(2): 314 - 346. [Abstract] [Full Text] [PDF]

				P. C. Adamson, B. C. Widemann, G. H. Reaman, N. L. Seibel, R. F. Murphy, A. F. Gillespie, and F. M. Balis A Phase I Trial and Pharmacokinetic Study of 9-cis-Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group Study Clin. Cancer Res., October 1, 2001; 7(10): 3034 - 3039. [Abstract] [Full Text] [PDF]

				V. A. Papadimitrakopoulou, J. Izzo, L. Mao, J. Keck, D. Hamilton, D. M. Shin, A. El-Naggar, P. den Hollander, D. Liu, W. N. Hittelman, et al. Cyclin D1 and p16 Alterations in Advanced Premalignant Lesions of the Upper Aerodigestive Tract: Role in Response to Chemoprevention and Cancer Development Clin. Cancer Res., October 1, 2001; 7(10): 3127 - 3134. [Abstract] [Full Text] [PDF]

				S. M. Lippman and M. R. Spitz Lung Cancer Chemoprevention: An Integrated Approach J. Clin. Oncol., September 15, 2001; 19(90001): 74s - 82. [Abstract] [Full Text] [PDF]

				D. M. Shin, F. R. Khuri, B. Murphy, A. S. Garden, G. Clayman, M. Francisco, D. Liu, B. S. Glisson, L. Ginsberg, V. Papadimitrakopoulou, et al. Combined Interferon-Alfa, 13-cis-Retinoic Acid, and Alpha-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II Trial J. Clin. Oncol., June 15, 2001; 19(12): 3010 - 3017. [Abstract] [Full Text] [PDF]

				S. M. Lippman, J. J. Lee, D. D. Karp, E. E. Vokes, S. E. Benner, G. E. Goodman, F. R. Khuri, R. Marks, R. J. Winn, W. Fry, et al. Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer J Natl Cancer Inst, April 18, 2001; 93(8): 605 - 618. [Abstract] [Full Text] [PDF]

				F. R. Khuri, J. S. Lee, S. M. Lippman, J. J. Lee, S. Kalapurakal, R. Yu, J. Y. Ro, R. C. Morice, W. K. Hong, and W. N. Hittelman Modulation of Proliferating Cell Nuclear Antigen in the Bronchial Epithelium of Smokers Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 311 - 318. [Abstract] [Full Text]

				J. Kim, D. M. Shin, A. El-Naggar, J. S. Lee, C. Corrales, S. M. Lippman, W. K. Hong, and W. N. Hittelman Chromosome Polysomy and Histological Characteristics in Oral Premalignant Lesions Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 319 - 325. [Abstract] [Full Text]

				J. L. Clifford, A. L. Sabichi, C. Zou, X. Yang, V. E. Steele, G. J. Kelloff, R. Lotan, and S. M. Lippman Effects of Novel Phenylretinamides on Cell Growth and Apoptosis in Bladder Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 391 - 395. [Abstract] [Full Text]

				S. M. Lippman and L. M. Matrisian Protease Inhibitors in Oral Carcinogenesis and Chemoprevention Clin. Cancer Res., December 1, 2000; 6(12): 4599 - 4603. [Full Text]

				W. K. Hong, M. R. Spitz, and S. M. Lippman Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets J. Clin. Oncol., November 1, 2000; 18(90001): 9s - 18. [Full Text] [PDF]

				M. Shalev, T. C. Thompson, A. Frolov, S. M. Lippman, W. K. Hong, H. Fritsche, and D. Kadmon Effect of 13-cis-Retinoic Acid on Serum Prostate-specific Antigen Levels in Patients with Recurrent Prostate Cancer after Radical Prostatectomy Clin. Cancer Res., October 1, 2000; 6(10): 3845 - 3849. [Abstract] [Full Text]

				K. Wu, H.-T. Kim, J. L. Rodriquez, D. Munoz-Medellin, S. K. Mohsin, S. G. Hilsenbeck, W. W. Lamph, M. M. Gottardis, M. A. Shirley, J. G. Kuhn, et al. 9-cis-Retinoic Acid Suppresses Mammary Tumorigenesis in C3(1)-Simian Virus 40 T Antigen-transgenic Mice Clin. Cancer Res., September 1, 2000; 6(9): 3696 - 3704. [Abstract] [Full Text]

				N. van Zandwijk, O. Dalesio, U. Pastorino, N. de Vries, and H. van Tinteren EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer J Natl Cancer Inst, June 21, 2000; 92(12): 977 - 986. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, C. C. Sigman, K. M. Johnson, C. W. Boone, P. Greenwald, J. A. Crowell, E. T. Hawk, and L. A. Doody Perspectives on Surrogate End Points in the Development of Drugs that Reduce the Risk of Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2000; 9(2): 127 - 137. [Abstract] [Full Text]

				S. M. Lippman and R. Lotan Advances in the Development of Retinoids as Chemopreventive Agents J. Nutr., February 1, 2000; 130(2): 479 - 479. [Abstract] [Full Text]

				Y. Lotan, X. C. Xu, M. Shalev, R. Lotan, R. Williams, T. M. Wheeler, T. C. Thompson, and D. Kadmon Differential Expression of Nuclear Retinoid Receptors in Normal and Malignant Prostates J. Clin. Oncol., January 1, 2000; 18(1): 116 - 116. [Abstract] [Full Text] [PDF]

				J. W. Bacus, C. W. Boone, J. V. Bacus, M. Follen, G. J. Kelloff, V. Kagan, and S. M. Lippman Image Morphometric Nuclear Grading of Intraepithelial Neoplastic Lesions with Applications to Cancer Chemoprevention Trials Cancer Epidemiol. Biomarkers Prev., December 1, 1999; 8(12): 1087 - 1094. [Abstract] [Full Text]

				J. L. Mulshine Reducing Lung Cancer Risk* : Early Detection Chest, December 1, 1999; 116 (2009): 493S - 496S. [Abstract] [Full Text] [PDF]

				S. M. Lippman and P. H. Brown Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost J Natl Cancer Inst, November 3, 1999; 91(21): 1809 - 1819. [Full Text] [PDF]

				W. McCaskill-Stevens, E. T. Hawk, P. J. Flynn, and S. M. Lippman National Cancer Institute-Supported Cancer Chemoprevention Research: Coming of Age J. Clin. Oncol., November 1, 1999; 17(90001): 53 - 62. [Full Text] [PDF]

				V. A. Papadimitrakopoulou, G. L. Clayman, D. M. Shin, J. N. Myers, A. M. Gillenwater, H. Goepfert, A. K. El-Naggar, J. S. Lewin, S. M. Lippman, and W. K. Hong Biochemoprevention for Dysplastic Lesions of the Upper Aerodigestive Tract Arch Otolaryngol Head Neck Surg, October 1, 1999; 125(10): 1083 - 1089. [Abstract] [Full Text] [PDF]

				X.-C. Xu, X. Liu, E. Tahara, S. M. Lippman, and R. Lotan Expression and Up-Regulation of Retinoic Acid Receptor-{beta} Is Associated with Retinoid Sensitivity and Colony Formation in Esophageal Cancer Cell Lines Cancer Res., May 1, 1999; 59(10): 2477 - 2483. [Abstract] [Full Text] [PDF]

				S. R. Ritland and S. J. Gendler Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression Carcinogenesis, January 1, 1999; 20(1): 51 - 58. [Abstract] [Full Text] [PDF]

				V. L. Seewaldt, E. C. Dietze, B. S. Johnson, S. J. Collins, and M. B. Parker Retinoic Acid-mediated G1-S-Phase Arrest of Normal Human Mammary Epithelial Cells Is Independent of the Level of p53 Protein Expression Cell Growth Differ., January 1, 1999; 10(1): 49 - 59. [Abstract] [Full Text]

				M.W. Lingen Angiogenesis in the Development of Head and Neck Cancer and Its Inhibition By Chemopreventive Agents Critical Reviews in Oral Biology & Medicine, January 1, 1999; 10(2): 153 - 164. [Abstract] [Full Text] [PDF]

				W. K. Hong and M. B. Sporn Recent Advances in Chemoprevention of Cancer Science, November 7, 1997; 278(5340): 1073 - 1077. [Abstract] [Full Text]

				B. F. Trump Mechanisms of Toxicity and Carcinogenesis Toxicol Pathol, November 1, 1995; 23(6): 775 - 827. [PDF]

				R. Lotan, X.-C. Xu, S. M. Lippman, J. Y. Ro, J. S. Lee, J. J. Lee, and W. K. Hong Suppression of Retinoic Acid Receptor-{beta} in Premalignant Oral Lesions and Its Up-Regulation by Isotretinoin N. Engl. J. Med., May 25, 1995; 332(21): 1405 - 1411. [Abstract] [Full Text] [PDF]